Plant Compounds Show Promise for Fibromyalgia Pain and Inflammation
New review reveals how phytonutrients from fruits and vegetables may help reduce fibromyalgia symptoms through multiple biological pathways.
Summary
This comprehensive review examined how plant-derived compounds (phytonutrients) might help manage fibromyalgia symptoms. Researchers analyzed studies on Mediterranean diets, specific supplements like curcumin and CoQ10, and gut microbiome changes. They found consistent evidence that fibromyalgia patients have increased oxidative stress and reduced antioxidant defenses. Plant-based dietary patterns showed improvements in pain, fatigue, and sleep quality, while certain supplements demonstrated symptom benefits. However, effects on inflammation markers were mixed, and study quality varied significantly across the research.
Detailed Summary
Fibromyalgia affects 2.1% of the global population with chronic widespread pain, fatigue, and sleep disturbances. This narrative review synthesized evidence on how phytonutrients—plant compounds like polyphenols, flavonoids, and carotenoids—might address the underlying mechanisms of fibromyalgia through antioxidant, anti-inflammatory, and gut microbiome-modulating effects.
The researchers conducted a comprehensive search across four major databases, examining human studies and relevant animal models published between 2005-2025. They found consistent evidence that fibromyalgia patients exhibit significantly reduced total antioxidant capacity and lower levels of key antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase), with these reductions correlating inversely with disease severity scores and pain ratings.
Clinical trials of plant-based dietary patterns, particularly Mediterranean-type and low-FODMAP diets, demonstrated improvements in pain intensity, fatigue, sleep quality, and gastrointestinal symptoms, along with modest gains in quality of life measures. Specific supplement trials showed mixed but promising results: coenzyme Q10, curcumin-based formulations, L-carnitine, and certain probiotics suggested beneficial effects on symptoms, while others showed little impact. Microbiome studies revealed that fibromyalgia patients have reduced butyrate-producing bacteria and altered microbial metabolites, changes that early dietary or probiotic interventions may partially address.
Preclinical studies identified SIRT1, a protein involved in cellular stress response and energy metabolism, as a potential mediator of phytonutrient benefits, though human data remains limited. The review noted significant methodological heterogeneity across studies, with often inadequate reporting of safety, dosage, and formulation details. The authors concluded that while current evidence supports phytonutrient-rich approaches as adjuncts to standard fibromyalgia care, well-designed randomized trials with standardized outcomes are needed to identify the most effective strategies and patient subgroups most likely to benefit.
Key Findings
- Fibromyalgia patients showed significantly reduced total antioxidant capacity and lower antioxidant enzyme levels that correlated inversely with disease severity scores
- Mediterranean-type and low-FODMAP diets demonstrated improvements in pain intensity, fatigue, sleep quality, and gastrointestinal symptoms in clinical trials
- Coenzyme Q10, curcumin-based formulations, L-carnitine, and specific probiotics showed beneficial effects on fibromyalgia symptoms in supplement trials
- Fibromyalgia patients exhibited reduced abundance of butyrate-producing bacteria including Faecalibacterium prausnitzii, Lachnospiraceae, and Bifidobacteriaceae
- Serum malondialdehyde and C-reactive protein levels were significantly higher in fibromyalgia patients compared to healthy controls in case-control studies
- Effects on inflammatory markers were conflicting across studies, with inconsistent results for cytokine levels and inflammatory biomarkers
- SIRT1 protein levels were inversely correlated with pain intensity ratings in chronic pain patients, suggesting a potential therapeutic target
Methodology
This narrative review followed SANRA guidelines and searched PubMed, Web of Science, Scopus, and ScienceDirect for studies published 2005-2025. Studies were restricted to peer-reviewed journals in top three quartiles by impact factor. Quality assessment focused on FM diagnosis clarity, sample size adequacy, phytonutrient exposure description, and outcome measures, though formal risk-of-bias tools were not applied due to study heterogeneity.
Study Limitations
The authors noted significant methodological heterogeneity across included studies, with often inadequate reporting of safety, dosage, and formulation details. Most human studies were small with limited sample sizes. The narrative review design prevented formal evidence grading, and the overall certainty of evidence should be regarded as limited. Many studies lacked proper control of confounding factors.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.